Clinical Trials Logo

Clinical Trial Summary

Randomised, double-blind, placebo-controlled study evaluating the effects of miltefosine on skin lesions in patients with treatment resistant chronic urticaria. Treatment resistance is defined by insufficient treatment response after a minimum of 1 week therapy with the maximum labelled dose of a non-sedating antihistamine. Eligible subjects will be enrolled at baseline 8 (+/- 1) days after screening. 75 Patients will be randomised in a 2:1 ratio to one of the following treatment groups as add-on to the ongoing therapy with a non-sedating antihistamine for treatment period of 4 weeks: 25 placebo and 50 active drug Efficacy and safety evaluations are done at baseline day 7, 14, 21 safety, only) and 28 (or end of treatment) and at day 56 (28 days after end of treatment).


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01170949
Study type Interventional
Source Charite University, Berlin, Germany
Contact
Status Terminated
Phase Phase 2
Start date September 2008
Completion date April 2010

See also
  Status Clinical Trial Phase
Completed NCT02435238 - AWARE - Chronic Urticaria N/A
Not yet recruiting NCT05513079 - Positive Psychotherapy-Based Counseling (PPT) N/A
Terminated NCT02047136 - Dietary Treatment for Chronic Urticaria N/A
Completed NCT01803763 - Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients Phase 2/Phase 3
Completed NCT00598611 - Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU) Phase 3
Completed NCT01610128 - Development of an Urticaria Control Test N/A
Completed NCT02285049 - Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test N/A
Completed NCT02285023 - The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire
Completed NCT01715740 - Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria Phase 3
Completed NCT01960283 - Methotrexate in the Treatment of Chronic Idiopathic Urticaria Phase 3
Completed NCT00481676 - Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria Phase 2
Completed NCT01713725 - Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria Phase 2
Completed NCT01250652 - Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses Phase 4
Completed NCT01111136 - Stress Intervention for Chronic Urticaria N/A
Recruiting NCT01425593 - T Cell Function in Chronic Idiopathic Urticaria N/A
Completed NCT00628108 - Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months Phase 3
Completed NCT00619801 - Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin Phase 3
Completed NCT00737451 - Association of Thyroid Autoimmunity and Chronic Urticaria N/A
Completed NCT01284426 - Natural History of Chronic Urticaria N/A
Withdrawn NCT01073852 - Hydroxychloroquine Efficacy in Chronic Urticaria N/A